New Data on Investigational Agent Belatacept in Kidney Transplant Recipients to be Presented at 2011 American Transplant Congress

Release Date: Monday, April 25, 2011 10:00 am EDT

Terms: R&D News

Dateline City: PRINCETON, N.J.

PRINCETON, N.J.--(BUSINESS WIRE)--New data on belatacept, an investigational selective T cell costimulation blocker being studied for use in renal transplantation by Bristol-Myers Squibb Company (NYSE:BMY), will be presented at the American Transplant Congress April 30 - May 4, 2011 in Philadelphia. In total, 21 abstracts from company-sponsored studies will be presented during the congress, including seven oral presentations related to kidney transplantation. The data being presented highlights the broad clinical program for belatacept, a key compound supporting Bristol-Myers Squibb’s strategy to discover and develop targeted therapies for serious diseases.

Key data being presented include:

- Three-Year Outcomes from BENEFIT: A Phase III Study of Belatacept vs. Cyclosporine in Kidney Transplant Recipients
- 3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies
- Renal Function at 2 Years in Kidney Transplant Recipients Switched from Cyclosporine or Tacrolimus to Belatacept: Results from the Long-Term Extension of a Phase II Study
- Three year Outcomes by Donor Type in Phase III Studies of Belatacept vs. Cyclosporine in Kidney Transplantation (BENEFIT & BENEFIT-EXT)

"Transplant patients often face multiple medical challenges following surgery" said Brian Daniels, M.D., senior vice president, Global Development and Medical Affairs, Bristol-Myers Squibb. "The breadth of Bristol-Myers Squibb's clinical data on belatacept at the American Transplant Congress demonstrates our ongoing commitment to address the unmet medical needs of patients in the renal transplant community."

The full schedule of clinical presentations at the American Transplant Congress is as follows:

<table>
<thead>
<tr>
<th>Session Date and Time</th>
<th>Presentation Title</th>
<th>Lead Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 1, 2011 4:12 p.m.</td>
<td>The Clinical Implications of Acute Rejection in Contemporary Kidney Transplantation</td>
<td>M. Schnitzler Saint Louis University St. Louis, MO</td>
</tr>
<tr>
<td>Room 201 Concurrent Session 13 (4:00 p.m. – 5:30 p.m.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2, 2011 2:15 p.m.</td>
<td>Lymphoproliferative Disorders After Kidney Transplantation: Comparison and Validation in Two Large Registries and Association with Outcomes</td>
<td>B. Kasiske Hennepin County Medical Center Minneapolis, MN</td>
</tr>
<tr>
<td>Room 107 Concurrent Session 34 (2:15 p.m. – 3:45 p.m.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2, 2011 2:39 p.m.</td>
<td>Renal Function at 2 Years in Kidney Transplant Recipients Switched from Cyclosporine or Tacrolimus to Belatacept: Results from the Long-Term Extension of a Phase II Study</td>
<td>J. Grinyó University Hospital of Bellvitge Barcelona, Spain</td>
</tr>
<tr>
<td>Room 201 Concurrent Session 32 (2:15 p.m. – 3:45 p.m.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2, 2011 2:51 p.m.</td>
<td>Three-Year Outcomes from BENEFIT: A Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients</td>
<td>F. Vincenti Univ. of California San Francisco, CA</td>
</tr>
<tr>
<td>Room 201 Concurrent Session 32 (2:15 p.m. – 3:45 p.m.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
May 2, 2011
3:03 p.m.
Room 201
Concurrent Session 32
(2:15 p.m. – 3:45 p.m.)
3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies
C. Larsen
Emory University
Atlanta, GA

May 2, 2011
3:15 p.m.
Room 201
Concurrent Session 32
(2:15 p.m. – 3:45 p.m.)
Three year Outcomes by Donor Type in Phase III Studies of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT & BENEFIT-EXT)
S. Florman
Mount Sinai Medical Center
New York, NY

May 2, 2011
3:27 p.m.
Room 201
Concurrent Session 32
(2:15 p.m. – 3:45 p.m.)
Renal Function in Patients Treated with Belatacept- or Cyclosporine-based Regimens at Year 3 in the BENEFIT and BENEFIT-EXT Studies
A. Durbach
Bicêtre Hospital, Kremlin Bicêtre, France

May 3, 2011
9:30 a.m.
Hall C
Plenary Session (III)
(8:30 a.m. – 10:00 a.m.)
Belatacept-based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience from a Phase II Study
G. Klintmalm
Baylor University Medical Center
Dallas, TX

Poster Presentations:

<table>
<thead>
<tr>
<th>Session Date and Time</th>
<th>Presentation Title</th>
<th>Lead Author</th>
</tr>
</thead>
</table>
| April 30, 2011
6:00 p.m.
Hall B | The Economic Implications of Acute Rejection in Contemporary Kidney Transplantation | M. Schnitzler
Saint Louis University
Saint Louis, MO |
| April 30, 2011
6:00 p.m.
Exhibit Hall B, Pennsylvania Convention Center Publication 789 Poster Board 188 6:00 p.m. – 8:00 p.m. | Renal Function and Cost of Medical Care among Commercially Insured Kidney Transplant Recipients | S. Bunnapradist
UCLA Medical Center
Los Angeles, CA |
| May 1, 2011
5:30 p.m.
Exhibit Hall B, Pennsylvania Convention Center Publication 1088 Poster Board 216 5:30 p.m. – 6:30 p.m. | Belatacept Compared with Cyclosporine in Renal Allograft Recipients of Extended Criteria Donor Kidneys: 3-year Outcomes from the Phase III BENEFIT-EXT Trial | J. Medina-Pestana
Hospital do Rim e Hipertensão
Sao Paolo, Brazil |
| May 1, 2011
5:30 p.m.
Exhibit Hall B, Pennsylvania Convention Center Publication 1087 Poster Board 215 5:30 p.m. – 6:30 p.m. | Likelihood of Improving or Sustaining Renal Function over Three Years with Belatacept or CsA: Insights from the BENEFIT Study | J. Grinyo
Hosp. Universitari De Bellvitge
Barcelona, Spain |
| May 1, 2011
5:30 p.m.
Exhibit Hall B, Pennsylvania Convention Center Publication 1091 Poster Board 219 5:30 p.m. – 6:30 p.m. | Three Year Outcomes in Black/African American Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies | S. Florman
Mount Sinai Medical Center
New York, NY |
May 1, 2011
5:30 p.m.
Exhibit Hall B,
Pennsylvania
Convention Center
Publication 1096
Poster Board 224
5:30 p.m. – 6:30 p.m.

<table>
<thead>
<tr>
<th>Rationale for Belatacept Less Intensive Regimen in Renal Transplant Recipients</th>
<th>J. Shen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb Princeton, NJ</td>
<td></td>
</tr>
</tbody>
</table>

May 1, 2011
5:30 p.m.
Exhibit Hall B,
Pennsylvania
Convention Center
Publication 1097
Poster Board 225
5:30 p.m. – 6:30 p.m.

<table>
<thead>
<tr>
<th>Predictable Pharmacokinetics, Pharmacodynamics, and Exposure-response of Belatacept Avert the Need of Therapeutic Drug Monitoring</th>
<th>J. Shen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb Princeton, NJ</td>
<td></td>
</tr>
</tbody>
</table>

May 1, 2011
5:30 p.m.
Exhibit Hall B,
Pennsylvania
Convention Center
Publication 1099
Poster Board 227
5:30 p.m. – 6:30 p.m.

<table>
<thead>
<tr>
<th>Health-Related Quality of Life After Kidney Transplantation: Results from Belatacept Clinical Trials</th>
<th>F. Dobbels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katholieke Universiteit Leuven Leuven, Belgium</td>
<td></td>
</tr>
</tbody>
</table>

May 1, 2011
5:30 p.m.
Exhibit Hall B,
Pennsylvania
Convention Center
Publication 1100
Poster Board 228
5:30 p.m. – 6:30 p.m.

<table>
<thead>
<tr>
<th>Patient Reports of Immunosuppressant Related Side-Effects After Kidney Transplantation: Results from the Belatacept Phase III Clinical Trial (BENEFIT)</th>
<th>F. Dobbels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katholieke Universiteit Leuven Leuven, Belgium</td>
<td></td>
</tr>
</tbody>
</table>

May 1, 2011
5:30 p.m.
Exhibit Hall B,
Pennsylvania
Convention Center
Publication 1075
Poster Board 203
5:30 p.m. – 6:30 p.m.

<table>
<thead>
<tr>
<th>In vitro studies show that Belatacept does not modulate B cell proliferation or T cell migration across brain microvascular endothelium</th>
<th>P. Davies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers-Squibb Princeton, NJ</td>
<td></td>
</tr>
</tbody>
</table>

May 1, 2011
5:30 p.m.
Hall B

<table>
<thead>
<tr>
<th>Expected Median Graft Survival Prediction for Belatacept Phase III Trial Outcomes in Kidney Transplantation</th>
<th>M. Schnitzler</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saint Louis University Saint Louis, MO</td>
<td></td>
</tr>
</tbody>
</table>

May 2, 2011
5:30 p.m.
Exhibit Hall B,
Pennsylvania
Convention Center
Publication 1175
Poster Board 27
5:30 p.m. – 6:30 p.m.

<table>
<thead>
<tr>
<th>Metabolic syndrome and new onset diabetes after transplant (NODAT): data from the international PORT study</th>
<th>B. Kasiske</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hennepin County Medical Center Minneapolis, MN</td>
<td></td>
</tr>
</tbody>
</table>

May 3, 2011
5:30 p.m.
Exhibit Hall B,
Pennsylvania
Convention Center
Publication 1525
Poster Board 99
5:30 p.m. – 6:30 p.m.

<table>
<thead>
<tr>
<th>Belatacept 6-Month Intravenous Toxicity Study in Monkeys</th>
<th>H. Haggerty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb New Brunswick, NJ</td>
<td></td>
</tr>
</tbody>
</table>

---

**About Belatacept**

Belatacept is an investigational agent under development by Bristol-Myers Squibb for the prophylaxis of organ rejection in adult patients receiving kidney transplants. The proposed trade name for belatacept is NULOJIX™.

Belatacept is a fusion protein designed to be a selective T cell co-stimulation blocker that binds to a specific site on certain cells of the immune system (i.e., antigen presenting cells) to block the second signal necessary to activate T cells, which are immune mediators involved in allograft rejection.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contact:
Bristol-Myers Squibb Company
Media:
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
Laura Hortas, 609-252-4587
laura.hortas@bms.com
or
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com

Ticker Slug:
Ticker: BMY
Exchange: NYSE